Imutec Corp. presented interim results of its Phase II clinicaltrial on Virulizin in patients with advanced malignantmelanoma last week at the Baylor College of Medicine ResearchSymposium in Houston.
The one-year survival rate of the patients treated withVirulizin, an immune response modifier extracted from bovinereticuloendothelium, was 39 percent compared with an 11percent one-year historical survival rate for patients withsimilar advanced stage III and IV malignant melanomas.
The 33-patient trial is being conducted at three hospitals inMexico.
Imutec (NASDAQIMUTF) of Toronto reported the preliminaryresults of these trials in January at the Second InternationalCongress on Biological Response Modifiers in San Diego.
(c) 1997 American Health Consultants. All rights reserved.